Marine Compounds as Neuroprotective Agents

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 312

Special Issue Editors

G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia
Interests: biochemistry; cell biology; mechanism of the biological activity of natural and synthetic biologically active substances; inflammation; new drug discovery; molecular targets; oncology; apoptosis; neurodegenerative disorders; cytoprotection; cells of the immune system
Special Issues, Collections and Topics in MDPI journals
G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia
Interests: cells of the immune system; the molecular mechanism of action; membrane receptors; neurodegenerative disorders; cytoptotection; inflammation; new drug discovery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neurodegenerative disorders are socially significant diseases; they occupy one of the first places in the world among diseases in the elderly, but today their symptoms begin to appear at an earlier age, and their frequency is steadily increasing. The most common diseases affecting the brain are Alzheimer's (AD), Parkinson's (PD), and multiple sclerosis.

Currently, no effective pharmacological treatment has been proposed that would block or treat the progression of neurodegenerative diseases. In the context of the rapid growth of morbidity, the discovery and development of new approaches and drugs for their treatment is an extremely urgent task. Natural compounds of organisms of marine origin are known for their structural diversity and a wide range of biological activity. Thus, marine natural compounds are a very promising chemical pool for discovering neuropharmacologically active compounds as potential drugs for AD, PD, multiple sclerosis, and cerebral ischemic stroke, among others.

This Special Issue is intended to present articles on current research on the neuroprotective properties of marine natural compounds. We particularly welcome work on the isolation and structure determination of new marine-derived compounds with neuroprotective activity in the latest in vitro and in vivo models in the field of neurodegenerative disease research.

Dr. Ekaterina S. Menchinskaya
Dr. Evgeny A. Pisliagin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • new drug discovery and development
  • neuroinflammation
  • neurodegenerative diseases
  • marine biologically active compounds
  • neuroprotection
  • central nervous system (CNS) disorders
  • Alzheimer’s disease (AD)
  • Parkinson’s disease (PD)
  • schizophrenia
  • dementia

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop